Work

Supplemental Figure 2 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial

Year: 2023

Type: supplementary-materials

Abstract: CD45-/Cytokeratin+ positive cell as seen in the left panel, with EGFR and MET FISH shown on the same cell in the right panel. This cell would be identified as a CTC based upon CD45/cytokeratin results even though neither EGFR nor MET amplification or polysomy are seen.

DOI: 10.1158/1078-0432.22468269

Authors: Masahiko Yanagita, Amanda J. Redig, Cloud P. Paweletz, Suzanne E. Dahlberg, Allison O'Connell, Nora Feeney, Myriam Taibi, David Boucher, Geoffrey R. Oxnard, Bruce E. Johnson, Daniel B. Costa, David M. Jackman, Pasi A. Jänne

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362405808

Cites:

Cited by:

Related to: 10